Showing results (41-50 of 70) with videos related to
Sort By:
Pageof 7
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 26, 2011
Inhibiting the mTOR pathway synergistically enhances cytotoxicity in ovarian cancer cells induced by etoposide through upregulation of c-JunHiroaki Itamochi, Tetsuro Oishi, Muneaki Shimada, et al.Healthcare (Basel, Switzerland)|April 23, 2022
Ovarian Endometrioid and Clear Cell Carcinomas with Low Prevalence of Microsatellite Instability: A Unique Subset of Ovarian Carcinomas Could Benefit from Combination Therapy with Immune Checkpoint Inhibitors and Other Anticancer AgentsYuki Nonomura, Kentaro Nakayama, Kohei Nakamura, et al.Human Cell|June 14, 2015
Establishment and mutation analysis of a novel malignant peritoneal mesothelioma cell line, TU-MM-1, using whole genome sequencingNao Oumi, Hiroaki Itamochi, Hiroaki Komatsu, et al.Healthcare (Basel, Switzerland)|September 25, 2019
A New Therapeutic Strategy for Recurrent Ovarian Cancer-Bevacizumab beyond Progressive DiseaseTadahiro Shoji, Hisashi Eto, Takanori Sato, et al.International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|August 9, 2017
Inhibition of Aurora Kinase A Synergistically Enhances Cytotoxicity in Ovarian Clear Cell Carcinoma Cell Lines Induced by Cisplatin: A Potential Treatment StrategyYohei Chiba, Seiya Sato, Hiroaki Itamochi, et al.International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|May 31, 2017
Serum Vascular Endothelial Growth Factor-A as a Prognostic Biomarker for Epithelial Ovarian CancerHiroaki Komatsu, Tetsuro Oishi, Hiroaki Itamochi, et al.BMC Women'S Health|May 4, 2021
Neutropenic enterocolitis-induced sepsis and disseminated intravascular coagulation after chemotherapy: a case reportMasako Ishikawa, Kentaro Nakayama, Sultana Razia, et al.International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|December 24, 2013
Checkpoint kinase inhibitor AZD7762 overcomes cisplatin resistance in clear cell carcinoma of the ovaryHiroaki Itamochi, Mayumi Nishimura, Nao Oumi, et al.Current Oncology (Toronto, Ont.)|May 27, 2022
Mutation Profiles of Ovarian Seromucinous Borderline Tumors in Japanese PatientsHiroki Sasamori, Kentaro Nakayama, Sultana Razia, et al.Current Oncology (Toronto, Ont.)|June 23, 2022
Promising Therapeutic Impact of a Selective Estrogen Receptor Downregulator, Fulvestrant, as Demonstrated In Vitro upon Low-Grade Serous Ovarian Carcinoma Cell LinesKamrunnahar Shanta, Kentaro Nakayama, Mohammad Mahmud Hossain, et al.Pageof 7